Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Intangibles (2020 - 2025)

Northwest Biotherapeutics' Intangibles history spans 6 years, with the latest figure at $5.3 million for Q4 2025.

  • Quarterly results put Intangibles at $5.3 million for Q4 2025, up 307.59% from a year ago — trailing twelve months through Dec 2025 was $5.3 million (up 307.59% YoY), and the annual figure for FY2025 was $5.3 million, up 307.59%.
  • Intangibles for Q4 2025 was $5.3 million at Northwest Biotherapeutics, up from $1.3 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $5.3 million in Q4 2025 to a low of $1.3 million in Q1 2021.
  • The 5-year median for Intangibles is $1.3 million (2021), against an average of $1.5 million.
  • The sharpest move saw Intangibles changed 0.0% in 2021, then skyrocketed 307.59% in 2025.
  • Year by year, Intangibles stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then changed by 0.0% to $1.3 million in 2023, then changed by 0.0% to $1.3 million in 2024, then skyrocketed by 307.59% to $5.3 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $5.3 million, $1.3 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.